Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Pfizer
(NY:
PFE
)
28.71
-0.17 (-0.59%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 15, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Pfizer
< Previous
1
2
...
10
11
12
13
14
15
16
17
18
...
33
34
Next >
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Univar Solutions Inc. (NYSE - UNVR), Oak Street Health (NYSE – OSH), Seagen Inc. (Nasdaq - SGEN), U.S. Xpress Enterprises, Inc. (NYSE – USX)
April 04, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Pfizer/BioNTech
April 04, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
FDA Accepts Pfizer’s Supplemental New Drug Applications for BRAFTOVI + MEKTOVI
April 04, 2023
From
Pfizer Inc.
Via
Business Wire
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) Lead NanoAb Candidate Holds Significant Advantages to Existing Therapies
April 03, 2023
Via
Investor Brand Network
Exposures
COVID-19
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
March 28, 2023
Clinical-stage biotechnology company Viking Therapeutics, Inc. (NASDAQ: VKTX) stock jumped more than 50% on positive Phase 1 data on its novel dual GLP-1/GLP
Via
MarketBeat
Don't Be Fooled by These 3 Value Traps
March 28, 2023
Approximately one out of every ten U.S. listed stocks have a positive P/E ratio less than 10. Some are justifiably cheap; others are merely fool’s gold.
Via
MarketBeat
Smartsheet Can Bolster Workflow Ecosystems and Your Portfolio
March 28, 2023
Cloud-based collaborative work management software provider Smartsheet Inc. (NASDAQ: SMAR) is an under-the-radar name growing at 35%.
Via
MarketBeat
BioNTech Is Ripe For A Rebound In 2023
March 27, 2023
BioNTech had a strong quarter and may become a takeover target due to its healthy pipeline and a looming patent cliff for big pharma.
Via
MarketBeat
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Oak Street Health (NYSE – OSH), Seagen Inc. (Nasdaq - SGEN), Provention Bio Inc. (Nasdaq - PRVB), Kimball International, Inc. (Nasdaq – KBAL)
March 23, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years?
March 22, 2023
By Julian Richard, Benzinga
Via
TheNewswire.com
Exposures
Product Safety
3 Dividend Contenders to Buy Now for Long-Term Gains Later
March 22, 2023
Dividend stocks have a role to play in any portfolio, and this article highlights three dividend contenders that you can buy now to get long-term gains later
Via
MarketBeat
Pfizer Invites Public to View and Listen to Webcast of May 2 Conference Call with Analysts
March 21, 2023
From
Pfizer Inc.
Via
Business Wire
Why did Sarepta Therapeutics Stock Plummet?
March 21, 2023
SRPT stock fell 20% after the FDA changed course on their new DMD treatment approval. The stock remains strong with an encouraging outlook and a mod Buy rating.
Via
MarketBeat
Exposures
Product Safety
A Company With Solutions Against Emerging COVID Variants And Other Viral Infections To Combat Future Pandemic Threats
March 20, 2023
By Ernest Dela Aglanu, Benzinga
Via
TheNewswire.com
Topics
Death
Economy
Exposures
COVID-19
Death
Economy
MarketBeat Week in Review – 3/13 - 3/17
March 18, 2023
The first triple witching day of 2023 is a fitting way to end a wild week. As you take some time to relax, here are some of our most popular stories this week
Via
MarketBeat
Topics
ETFs
Economy
Exposures
Interest Rates
FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for Pfizer’s PAXLOVID™
March 16, 2023
From
Pfizer Inc.
Via
Business Wire
Pfizer’s Latest Acquisition Strengthens the Case for PFE Stock
March 15, 2023
Pfizer's merger with Seagen will strengthen the company's already strong oncology portfolio and perhaps boost the case for owning PFE stock
Via
MarketBeat
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Qualtrics (Nasdaq - XM), Seagen Inc. (Nasdaq - SGEN), Provention Bio Inc. (Nasdaq - PRVB), Kimball International, Inc. (Nasdaq – KBAL)
March 13, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
Pfizer Invests $43 Billion to Battle Cancer
March 13, 2023
From
Seagen Inc.
Via
Business Wire
Pfizer’s ZAVZPRET™ (zavegepant) Migraine Nasal Spray Receives FDA Approval
March 10, 2023
From
Pfizer Inc.
Via
Business Wire
BRTX’s ThermoStem®: A New Weapon In The Fight Against Metabolic Syndrome
March 09, 2023
By Julian Richard, Benzinga
Via
TheNewswire.com
Schrodinger is an AI-Powered Drug Discovery Developer to Watch
March 08, 2023
Drug discovery software developer Schrodinger Inc. (NASDAQ: SDGR) stock has been trying to recover after plummeting over 80% off its all-time high of $117
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Product Safety
Lucy Scientific Discovery, Inc. Scores Major Milestone, Transitions To Revenue Generating Company With First Commercial Sale Of Psilocybin ($LSDI)
March 01, 2023
Via
AB Newswire
Lucira Stock Jumps over 250% on FDA Approval, Beware Chapter 11
March 01, 2023
Lucira Health Inc. (NASDAQ: LHDX) shares spiked up 264% to close at $0.52 on a massive 278 million shares traded on the announcement of FDA approval for its
Via
MarketBeat
Topics
Initial Public Offering
Exposures
COVID-19
Product Safety
Securities Market
Pfizer Receives Positive FDA Advisory Committee Votes Supporting Potential Approval for Vaccine Candidate to Help Combat RSV in Older Adults
February 28, 2023
From
Pfizer Inc.
Via
Business Wire
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
February 27, 2023
From
Pfizer Inc.
Via
Business Wire
Analysts Holding As Pfizer Waits On Two Phase 3 Studies
February 24, 2023
Pfizer has two products with great potential, waiting on phase-3 study results. The resulting revenue increase should also improve share value.
Via
MarketBeat
Topics
Bankruptcy
Exposures
Financial
Legal
Dr. Harte asks: “‘Public Health?’ THE serious hazard to health?”
February 22, 2023
Corte Madera, California, United States - 02-22-2023 (PR Distribution™) -
Via
PR Distribution
Exposures
COVID-19
Pfizer’s Elranatamab Receives FDA and EMA Filing Acceptance
February 22, 2023
From
Pfizer Inc.
Via
Business Wire
What Are Dividend Payment Dates?
February 21, 2023
What are dividend payment dates? The payment date is the day a company pays its eligible shareholders dividends. Learn more.
Via
MarketBeat
< Previous
1
2
...
10
11
12
13
14
15
16
17
18
...
33
34
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.